Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses." "Schema di trattamento con lanreotide ad alte dosi in pazienti acromegalici scarsamente responsivi al trattamento con dosi standard".

Trial Profile

Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses." "Schema di trattamento con lanreotide ad alte dosi in pazienti acromegalici scarsamente responsivi al trattamento con dosi standard".

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Sponsors Ipsen SPA
  • Most Recent Events

    • 16 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 27 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top